Autres langues Ascentage Pharma Group International

Actions

6855

KYG0519B1023

Temps Différé Hong Kong S.E. Autres places de cotation 07:15:53 26/06/2024			Varia. 5j.	Varia. 1 janv.
25,45 ^HKD	+0,59%		-3,78%	-6,78%

21/06	Ascentage Pharma Group conclut un accord de souscription d'actions de 75 millions de dollars avec Takeda International	MT
18/06	Ascentage Pharma Group International présente les résultats de trois études à l'EHA 2024	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Ascentage Pharma Group Completes $75 Million Share Subscription Deal with Takeda International	21/06
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda	21/06
Ascentage Pharma Group International announced that it has received $74.999999 million in funding from Takeda International - Uk Branch	20/06
Ascentage Pharma Group International Present Results from Three Studies at EHA 2024	18/06
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib	18/06
Ascentage Pharma to Issue Over 24 Million Shares to Takeda International	17/06
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	14/06
Ascentage Pharma Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient Gist Approved by the China CDE	11/06
Ascentage Pharma Group International Announces Board and Committee Changes	10/06
Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%	05/06
Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM	05/06
Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC	02/06
Ascentage Pharma to Present Four Studies on Anti-Cancer Drugs at US Oncology Meet; Shares Fall 4%	24/05
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting	24/05
EHA 2024 \| Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress	16/05
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	14/05
Ascentage Pharma to Present Four Studies at US Oncology Meet	25/04
Ascentage Pharma Chairman Boosts Stake in Firm	09/04
Ascentage Pharma Group Directors Acquire Company Shares	04/04
Ascentage Pharma Widens Loss by Nearly 5% in 2023	28/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ascentage Pharma Group International

Actions

6855

KYG0519B1023

Autres langues

Filtres